Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)
Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus
Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus Professional…
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in localized prostate cancer
Lucid Diligence Brief: Candel Therapeutics $100m funding for CAN-2409 in…
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement
Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…
Lucid Diligence Brief: Danaher to acquire Masimo in $9.9bn all-cash deal
Lucid Diligence Brief: Danaher to acquire Masimo in $9.9bn all-cash deal…
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic editing to siRNA obesity therapies
Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic…
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal oncology $1.5B deal
Lucid Diligence Brief: Genhouse Bio and Gilead in GH31 synthetic-lethal…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership
Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership…
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…